Revvity Inc (STU:PKN)
€ 112.65 4.2 (3.87%) Market Cap: 13.59 Bil Enterprise Value: 15.56 Bil PE Ratio: 57.01 PB Ratio: 1.82 GF Score: 80/100

PerkinElmer Inc at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript

Mar 21, 2023 / 06:15PM GMT
Release Date Price: €114.56 (+0.77%)
Paul Richard Knight
KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst

Hi. This is Paul Knight, the analyst at KeyBanc on the life science industry. With me today, had been covering PerkinElmer, which I have followed since 1999 when they were known as EG&G, which, again, fast forward, I think, Steve, there will be no longer PerkinElmer soon. But Steve Willoughby, Director of Investor Relations; Alan Fletcher, Head of the Life Science Group. But Steve, I think if you could provide a little bit of intro yourself and for Alan, that would be a good place to start.

Stephen Barr Willoughby
PerkinElmer, Inc. - Senior VP of IR & Head of ESG

Very good. Yes. Paul, thanks for having us. Happy to be here. So Steve Willoughby, I lead IR as well as ESG for the company. I've been here just about 2 years, after also being on the sell side for nearly 20 years before joining the corporate side. And so I've also known the company not since '99, but for quite a while, externally and then, obviously, for the last 2 years on this side of the fence.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot